
Understanding the Safety Profile of Oral JAK Inhibitors in Atopic Dermatitis
Video content above is prompted by the following: Oral JAK inhibitors demonstrate an extensive safety profile across multiple age groups and indications, with upadacitinib approved for use in patients as young as 2 years for juvenile idiopathic arthritis …